5th Mar 2015 10:58
LONDON (Alliance News) - Tissue Regenix Ltd said Thursday the first UK patient has received a partial knee meniscal replacement using its OrthoPure XM treatment for damage or tears to the meniscus knee cartilage, as part of a clinical safety study of the product.
The company said the study is being conducted to secure a CE mark, to allow for the product to be launched in the EU in 2016.
The treatment was used to replace damaged sections of the knee meniscus using Tissue Regenix's decellularised tissue, meaning donor tissue that has had its DNA removed to leave behind a natural scaffold that can then be placed in the wound.
"It is early days with this trial, but I am pleased the Ortho team have achieved this important milestone in our progress towards launch. We are fortunate to be working with surgeons who recognise the importance of innovative biologic solutions to this very common type of injury," said Commercial Director Peter Hamer in a statement.
Shares in Tissue Regenix have jumped on the announcement and are up 6.0% at 20.40 pence Thursday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Tissue Regenix Group